Bronnen:
Mok T, Ahn MJ, Han JY, et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol 35, 2017 (suppl; abstr 9005).,Cho BC, Ahn MJ, Lee JS, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. J Clin Oncol 35, 2017 (suppl; abstr 2069).
Mok T, Ahn MJ, Han JY, et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol 35, 2017 (suppl; abstr 9005).,Cho BC, Ahn MJ, Lee JS, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. J Clin Oncol 35, 2017 (suppl; abstr 2069).